首页|基于专利数据库对脉痹处方规律及核心中药的数据挖掘研究

基于专利数据库对脉痹处方规律及核心中药的数据挖掘研究

扫码查看
原文链接
  • 万方数据
  • 维普
目的 基于国家专利复方，探寻中医药干预脉痹的遣方用药规律。方法 计算机检索国家专利数据建库至2023年3月有关中医药干预脉痹的专利复方，运用Excel进行数据清洗和频次、性味、归经的统计，SPSS Modeler 18。0和R。4。3。1进行中药关联性及层次聚类分析，Cytoscape 3。9。1对共现网络进行可视化升级。结果 本研究纳入专利复方124项，涉及中药324味;高频中药包括丹参、黄芪等;药性以寒、温为主，药味以苦、甘、辛居多，归经主要归肝经;常见药对包括"黄芪-丹参"等;常用角药组合包含"山楂-丹参-川芎"等;层次聚类得到4组聚类组合。结论 专利复方治疗脉痹以活血祛瘀，化浊降脂，补益气血为主，本研究梳理了治疗脉痹的核心中药，以期为临床遣方用药和未来新药研发提供思路。
Research on data mining of vessel bi prescription rules and core Chinese medicine based on patent database
Objective To explore the rules of medicinal use of Chinese medicine in the intervention of vessel bi based on the national patent compound prescription.Methods The national patent database was searched by computer from inception to March 2023 on the patent compound prescription of traditional Chinese medicine intervention in vessel bi.Excel was used for data cleaning and statistics of frequency,nature and flavour,channel tropism.SPSS Modeler 18.0 and R.4.3.1 were used for traditional Chinese medicine correlation and hierarchical cluster analysis.Cytoscape 3.9.1 visually upgrade the co-occurring network.Results In this study,124 patent compound prescriptions were included,involving 324 kinds of traditional Chinese medicine.The high frequency Chinese medicine included Salviae Miltiorrhizae Radix Et Rhizoma,Astragali Radix,and so on.The drug natures were mainly cold and warm,and the drug flavours were mostly bitter,sweet,and pungent,and the main channel tropism was liver channel.Common drug pairs included"Astragali Radix and Salviae Miltiorrhizae Radix Et Rhizoma"and so on.Commonly used three drug combination included"Crataegi Fructus-Salviae Miltiorrhizae Radix Et Rhizoma-Chuanxiong Rhizoma"and so on.The hierarchical clustering resulted in four cluster combinations.Conclusion The patented compound prescription is mainly used to promote blood circulation and remove blood stasis,reduce turbidity and lipids,and supplement qi and blood.This study sorted out the core traditional Chinese medicine for the treatment of vessel bi,in order to provide ideas for clinical potential prescription medicine and future new drug research and development.

Vessel biAtherosclerosisCompound prescriptionPatentsData miningHierarchical clusteringBetween centralityPhi correlation coefficient

杨振宇、李纪新、李丙泉、顾晨浩、李晨、郭丹丹

展开 >

黑龙江中医药大学,黑龙江哈尔滨 150040

中国中医科学院西苑医院治未病中心,北京 100091

脉痹 动脉粥样硬化 复方 专利 数据挖掘 层次聚类 中介中心性 Phi相关系数

黑龙江省中医药科研项目黑龙江省中医药科研项目黑龙江省哈尔滨市科学技术局应用技术研究与开发项目

ZHY2020-148ZHY2023-1742017RAQXJ208

2024

10.20047/j.issn1673-7210.2024.06.04

中国医药导报
中国医学科学院

中国医药导报

CSTPCD
影响因子：1.759
ISSN：1673-7210
年,卷(期)：2024.21(6)
  • 33